Wednesday, 12 Dec 2018

You are here

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

  1. In a historical prospective cohort study, PPI use in RA (1:4) was associated with a doubling of risk for acute kidney injury (HZ 2.30: 1.26-4.20) but was only 2.2 AKI per 1000PY in RA/PPI+ vs 0.9/1000PY in RA without PPI. Thus depends on need for PPI https://t.co/TxqjAR7Y5Y
  2. In early arthritis clinics in Leeds and UK ERAS study (454 &895 pts), DMARD free remission seen in 15-9.4%; predictors included acute onset, short Sx duration, NO smoking, No Xray damage, Seronegativity, absent HLA shared epitope alleles https://t.co/3yulHyrS4O
  3. Shingrix captured 90% of shingles vaccine market, w/ greater efficacy & CDC endorsement, plus is NOT a live vaccine & could be used with biologics. While cost is the same, it has more nuisance side effect & no studies/data in RA, CTD. https://t.co/lycVu8JrQq
  4. Shingrix is an inactive, subunit vaccine for H. zoster, >50 yrs, given as 2 IM doses (0.5 mL each), 2nd dose 2-6 mos after 1st. Shingrix is more effective than Zostavax but has more side effects. Unlike Zostavax, Shingrix can be given to biologic pts. https://t.co/k4eUW9mbdO
  5. In Ireland, waiting time/list to see a pediatric rheumatologist has grown 33% from previous year, with 902 waiting — 543 were waiting more than 12 mos (was 302 Jan 2017). Stems from a delay in implementing a new model of care for paediatric rheumatology. https://t.co/0V2Xu9gRrC
  6. 2015 US Pharma donated $116 million to Pt advocacy groups. For example Patients for Biologics Safety & Access (who opposes biosimilar substitution and includes Crohn’s & Colitis, Arthritis & Lupus Foundations) accepted $9.1 million from drug companies https://t.co/i3WDjNHu6f
  7. Increased Comorbidity Burden in Lupus African Americans   
  8. SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus 
  9. ACR Projects Significant Manpower Shortages for 2030    
  10. Favorable Certolizumab Safety Profile in Pregnancy  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Do we know if Shingrix, with it's potent adjuvant, may cause RA to flare?

More Like This

RheumNow Podcast – Can RA Be Prevented (12.7.18)

Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:

Chronic Kidney Disease Increasing in the U.S.A.

JAMA has published the Global Burden of Disease (GBD) study showing that that, from 2002 to 2016, the US burden of chronic kidney disease (CKD) increased, with some states exhibiting more than twice the burden as others. The increase in burden was associated with increased metabolic and dietary risk exposure that manifested in increased probability of death due to diabetic CKD, especially for those between 20 to 55 years.  

RheumNow Podcast – To Needle or Not to Needle (11.30.18)

Dr. Jack Cush updates the news and reports from the past week at RheumNow.com:

Physical Activity Guidelines for Americans

The data are clear and disappointing: despite the well-known health benefits, four out of five US adults are not active physically.  JAMA has published the new US Physical Activity Guidelines for Americans, so that health professionals and policy makers can promote lifestyle changes and awareness of the the health benefits of physical activity.

The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)

Dr. Jack Cush reviews the news from the past week at RheumNow.com.